Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband (NASDAQ:NTRB) received final meeting minutes from a Sept 18, 2025 virtual face-to-face meeting with the US FDA regarding its lead product AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system. FDA confirmed the regulatory pathway as a 505(b)(2) NDA and provided CMC feedback on registration batch plans, manufacturing process validation, product specifications, stability testing, and planned Category 1 in vitro manipulation/extraction studies. Nutriband is incorporating FDA guidance as it advances toward an IND filing to support a Human Abuse Potential (HAP) clinical study. The company partners with Kindeva and cites a peak US sales potential of $80M–$200M. Nutriband holds patents in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.
Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.
Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.
Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.
Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.
The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).
Nutriband (NASDAQ: NTRB / NTRBW) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. Chairman Serguei Melnik will deliver a formal presentation including a fireside Q&A at 3:00 PM Eastern, with live questions from the virtual audience.
Registered, qualified investors may request scheduled 1x1 meetings with management by contacting Giorgia Pigato at Noble Capital Markets. The live webcast will be available via Channelchek and will be archived on the company website and Channelchek for 90 days. Registration for the live presentation is free for attendees.
Nutriband Inc. (NASDAQ:NTRB) has announced its participation in the upcoming MicroCap Rodeo Conference in New York City on September 25, 2025. Company Chairman Serguei Melnik will deliver a presentation at 10:00 AM, focusing on operational highlights, growth initiatives, and the company's AVERSA platform technology.
The presentation will be available via live webcast, and management will conduct one-on-one meetings with approved investors. Interested parties can register for the virtual presentation through the conference website at www.microcaprodeo.com.
Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.
The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB) has announced the exercise of warrants at a strike price of $6.43, generating gross proceeds of $5,306,000. The company will utilize these funds primarily for completing the clinical development of AVERSA Fentanyl and submitting its New Drug Application (NDA) to the FDA for marketing approval.
AVERSA Fentanyl is positioned to potentially become the first opioid patch with abuse deterrent properties. According to the Health Advances Aversa Fentanyl market analysis report 2022, the product could achieve peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ: NTRB) has announced its participation in the upcoming Emerging Growth Conference on August 20, 2025. The company's Chairman, Serguei Melnik, will deliver a presentation at 09:40 AM Eastern time for 30 minutes.
The interactive online event will allow shareholders and investors to engage directly with management through a Q&A session. Questions can be submitted in advance to Questions@EmergingGrowth.com or during the live event. For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
Nutriband (NASDAQ:NTRB) announced that CEO Gareth Sheridan will temporarily step down for three months to pursue candidacy in the Irish Presidential election. Chairman and President Serguei Melnik will serve as interim CEO during September and October 2025.
The company recently received FDA meeting approval for AVERSA Fentanyl, their abuse-deterrent opioid patch. The product has projected peak annual US sales potential of $80-200 million and is protected by patents in 46 countries. The company remains on track for its planned NDA filing in 2026.
FAQ
What is the current stock price of Nutriband (NTRBW)?
